Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis and limited treatments.
• The tumor microenvironment (TME) in PDAC is immunosuppressive, hindering immunotherapy.
• CXCR2+ myeloid-derived suppressor cells (MDSCs) infiltrate PDAC tumors and suppress anti-tumor immunity.

Purpose of the Study:

• To investigate the role of CXCR2 ligands in PDAC immunosuppression.
• To develop novel therapeutic strategies targeting the CXCR2 axis for PDAC immunotherapy.

Main Methods:

• Analysis of soluble factors from human and mouse PDAC cells.
• Assessment of myeloid cell migration towards PDAC-conditioned media.
• Development and testing of CXCR2 ligand-Fc fusion proteins ("superkines").

Main Results:

• PDAC cells secrete abundant CXCR2 ligands (CXCL8, CXCL5, CXCL1), dependent on KRAS and NFκB signaling.
• MDSCs are the predominant immune cells in PDAC tumors and express CXCR2.
• CXCR2 "superkines" effectively inhibited myeloid cell migration, outperforming existing inhibitors.

Conclusions:

• CXCR2 signaling axis is a key driver of myeloid cell recruitment in PDAC.
• CXCR2 "superkines" show potential for disrupting MDSC infiltration and enhancing immunotherapy in PDAC.